No Data
SKB BIO-B (06990.HK): Anti-PD-L1 Tagorelimab has been approved for marketing by the National Medical Products Administration.
Gelonghui, December 31st丨SKB BIO-B (06990.HK) announced that its innovative humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) known as Tagolisumab (formerly KL-A167) for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have previously failed second-line or above chemotherapy has been approved by the National Medical Products Administration (NMPA) in China for market release. This approval is primarily based on an open-label, multicenter, phase II clinical trial conducted in patients with recurrent or metastatic nasopharyngeal carcinoma who had previously experienced treatment failure after second-line or above systemic therapies.
Express News | Sichuan Kelun-Biotech Biopharmaceutical - Anti-Pd-L1 Tagitanlimab Approved for Marketing by Nmpa of China
Guosen: Continuously recommending Innovative Drugs and paying attention to investment opportunities in Medical Devices.
Currently, the Industry is undergoing significant supply-side structural reforms, and the collective procurement of Pharmaceuticals and Medical Devices is also nearing completion, with the expectation of entering a new growth cycle in 2025.
SKB Biopharma Avails of 300 Million Yuan Structured Deposits From China's Industrial Bank
SKB BIO-B (06990) subscribed to a total of 0.3 billion yuan in structured deposits from Industrial Bank.
SKB BIO-B (06990) announced that on December 17, 2024, the company signed with Industrial Bank...
Express News | Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe 2 Structured Deposits From Industrial Bank of RMB170 Mln and RMB130 Mln
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
